Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

A New, Atypical Case of Cobalamin F Disorder Diagnosed by Whole Exome Sequencing.

Deciphering Developmental Disorders Study Group, Constantinou P, D'Alessandro M, Lochhead P, Samant S, Bisset WM, Hauptfleisch C, Dean J.

Mol Syndromol. 2016 Feb;6(5):254-8. doi: 10.1159/000441134. Epub 2015 Oct 14.

2.

Fecal Microbiome in Epidemiologic Studies-Letter.

Drew DA, Lochhead P, Abu-Ali G, Chan AT, Huttenhower C, Izard J.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):869. doi: 10.1158/1055-9965.EPI-16-0063. Epub 2016 Mar 9. No abstract available.

PMID:
26961995
3.

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Lochhead PA, Clark J, Wang LZ, Gilmour L, Squires M, Gilley R, Foxton C, Newell DR, Wedge SR, Cook SJ.

Cell Cycle. 2016 Feb 16;15(4):506-18. doi: 10.1080/15384101.2015.1120915.

PMID:
26959608
4.

Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine.

Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, Qian ZR, Zhang X, Wu K, Nan H, Yoshida K, Milner DA Jr, Chan AT, Field AE, Camargo CA Jr, Williams MA, Giovannucci EL.

Epidemiology. 2016 Jul;27(4):602-11. doi: 10.1097/EDE.0000000000000471.

PMID:
26928707
5.

Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease.

Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, Chan AT.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):818-824.e6. doi: 10.1016/j.cgh.2016.01.016. Epub 2016 Feb 1.

PMID:
26844874
6.

Statistical methods for studying disease subtype heterogeneity.

Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, Poole EM, Tamimi R, Tworoger SS, Giovannucci E, Rosner B, Ogino S.

Stat Med. 2016 Feb 28;35(5):782-800. doi: 10.1002/sim.6793. Epub 2015 Dec 1.

PMID:
26619806
7.

Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.

Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian ZR, Kim SA, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, Pollak MN, Mantzoros CS, Harris CC, Giovannucci E, Fuchs CS, Cho E, Chan AT, Wu K, Ogino S.

J Natl Cancer Inst. 2015 Nov 23;108(4). pii: djv363. doi: 10.1093/jnci/djv363. Print 2016 Apr.

PMID:
26598515
8.

Molecular pathological epidemiology gives clues to paradoxical findings.

Nishihara R, VanderWeele TJ, Shibuya K, Mittleman MA, Wang M, Field AE, Giovannucci E, Lochhead P, Ogino S.

Eur J Epidemiol. 2015 Oct;30(10):1129-35. doi: 10.1007/s10654-015-0088-4. Epub 2015 Oct 7.

PMID:
26445996
9.

Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival.

Lochhead P, Nishihara R, Qian ZR, Mima K, Cao Y, Sukawa Y, Kim SA, Inamura K, Zhang X, Wu K, Giovannucci E, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Am J Clin Nutr. 2015 Nov;102(5):1134-41. doi: 10.3945/ajcn.115.115162. Epub 2015 Sep 30.

PMID:
26423386
10.

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M, Rowlinson RA, Baak LM, Gallo R, Balmanno K, Goodwin LM, Ward RA, Lochhead PA, Guichard S, Hudson K, Cook SJ.

Cell Mol Life Sci. 2016 Feb;73(4):883-900. doi: 10.1007/s00018-015-2032-x. Epub 2015 Sep 7.

11.

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.

Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, Cook SJ, Barallobre MJ, Arbonés ML.

EBioMedicine. 2015 Jan 17;2(2):120-34. doi: 10.1016/j.ebiom.2015.01.010. eCollection 2015 Feb.

12.

Initial experience of direct-to-test endoscopic ultrasonography for suspected choledocholithiasis.

Lochhead P, Phull P.

Scott Med J. 2015 May;60(2):85-9. doi: 10.1177/0036933015572276. Epub 2015 Feb 10.

PMID:
25673357
13.

Screening and surveillance for Barrett esophagus.

Lochhead P, Chan AT.

JAMA Intern Med. 2015 Feb;175(2):159-60. doi: 10.1001/jamainternmed.2014.6983. No abstract available.

14.

Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis.

Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian ZR, Kuchiba A, Kim SA, Mima K, Sukawa Y, Jung S, Zhang X, Wu K, Cho E, Chan AT, Meyerhardt JA, Harris CC, Fuchs CS, Ogino S.

J Natl Cancer Inst. 2014 Sep 4;106(9). pii: dju195. doi: 10.1093/jnci/dju195. Print 2014 Sep.

15.

Response.

Lochhead P, Meyerhardt JA, Fuchs CS, Ogino S.

J Natl Cancer Inst. 2014 Aug 11;106(8). pii: dju181. doi: 10.1093/jnci/dju181. Print 2014 Aug. No abstract available.

16.

SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.

Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K, Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S, Qian ZR.

Ann Surg Oncol. 2014 Dec;21(13):4164-73. doi: 10.1245/s10434-014-3888-y. Epub 2014 Jul 15.

17.

Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, Ogino S.

Am J Gastroenterol. 2014 Aug;109(8):1205-14. doi: 10.1038/ajg.2014.153. Epub 2014 Jun 17. Review.

18.

Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression.

Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S.

Mod Pathol. 2015 Jan;28(1):14-29. doi: 10.1038/modpathol.2014.81. Epub 2014 Jun 13. Review.

19.

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Mol Cancer. 2014 May 31;13:135. doi: 10.1186/1476-4598-13-135.

20.

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).

Ashford AL, Oxley D, Kettle J, Hudson K, Guichard S, Cook SJ, Lochhead PA.

Biochem J. 2014 Jan 1;457(1):43-56. doi: 10.1042/BJ20130461.

PMID:
24134204
Items per page

Supplemental Content

Loading ...
Write to the Help Desk